Johnson & Johnson with price, financials, news flow, and insider context in one page.
Johnson & Johnson is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where JNJ sits inside Healthcare and Drug Manufacturers - General, and the key financial markers that matter before moving into a fuller research workflow.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
This page is structured for research context, not a trade call. It gives you a clean read on where JNJ sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 24.06B | 5.24B | 1.47B |
| Q4 2025 | 24.56B | 5.12B | 5.47B |
| Q3 2025 | 23.99B | 5.15B | 8B |
| Q2 2025 | 23.74B | 5.54B | 2.48B |
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
Johnson & Johnson (JNJ) — questions investors ask
What is the current stock price of Johnson & Johnson (JNJ)?
Johnson & Johnson (JNJ) is trading at $235.66, down 2.16% in the latest session. The live price and one-year chart on this page update through the trading day.
What is Johnson & Johnson's market capitalization?
Johnson & Johnson has a market capitalization of about 567.28B, derived from the latest share price and shares outstanding.
When is Johnson & Johnson's next earnings date?
Johnson & Johnson is next expected to report earnings on Jul 15, 2026. The JNJ earnings page tracks the estimate and reporting history.
What is Johnson & Johnson's P/E ratio?
Johnson & Johnson trades at a forward price-to-earnings ratio of 18.53 — one measure of how the market is pricing its future earnings.
What is JNJ's 52-week trading range?
Over the past 52 weeks, JNJ has traded between $149.04 and $251.71.
What sector is Johnson & Johnson in?
Johnson & Johnson operates in the Healthcare sector, within the Drug Manufacturers - General industry.
Does Johnson & Johnson pay a dividend?
Johnson & Johnson currently carries a dividend yield of about 100.0%.
What is the analyst price target for JNJ?
The mean analyst price target for JNJ is $252.87, with an overall analyst view of Buy.
A public stock page should answer the first research questions before asking for a signup.
This JNJ page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.